UNICA IRIS Institutional Research Information System

CAOCCI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 491.031
NA - Nord America 16.514
AS - Asia 6.953
SA - Sud America 1.417
AF - Africa 147
OC - Oceania 59
Continente sconosciuto - Info sul continente non disponibili 11
Totale 516.132
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 483.379
US - Stati Uniti d'America 16.243
NL - Olanda 3.243
SG - Singapore 2.775
CN - Cina 2.538
SE - Svezia 1.243
BR - Brasile 1.175
UA - Ucraina 1.148
VN - Vietnam 553
DE - Germania 480
GB - Regno Unito 467
FI - Finlandia 405
FR - Francia 216
KR - Corea 215
IN - India 203
CA - Canada 163
HK - Hong Kong 113
AR - Argentina 96
AT - Austria 89
MX - Messico 76
PL - Polonia 70
JP - Giappone 64
RU - Federazione Russa 57
ZA - Sudafrica 57
BD - Bangladesh 56
IQ - Iraq 53
IR - Iran 53
TR - Turchia 52
AU - Australia 50
EC - Ecuador 45
IE - Irlanda 37
ID - Indonesia 33
BE - Belgio 31
PK - Pakistan 31
SA - Arabia Saudita 31
ES - Italia 30
MA - Marocco 23
AE - Emirati Arabi Uniti 22
MY - Malesia 22
CZ - Repubblica Ceca 21
CO - Colombia 20
VE - Venezuela 20
EG - Egitto 19
LT - Lituania 19
CL - Cile 16
TH - Thailandia 16
CH - Svizzera 14
UZ - Uzbekistan 14
IL - Israele 13
PY - Paraguay 13
UY - Uruguay 13
JO - Giordania 12
BG - Bulgaria 11
EU - Europa 11
KE - Kenya 11
RO - Romania 11
TN - Tunisia 11
KZ - Kazakistan 10
PE - Perù 10
PH - Filippine 10
BO - Bolivia 9
DK - Danimarca 9
LB - Libano 8
NP - Nepal 8
NZ - Nuova Zelanda 8
TW - Taiwan 8
AZ - Azerbaigian 7
DZ - Algeria 7
HU - Ungheria 7
PT - Portogallo 7
BY - Bielorussia 6
GR - Grecia 6
JM - Giamaica 6
OM - Oman 6
PA - Panama 5
PR - Porto Rico 5
AM - Armenia 4
DO - Repubblica Dominicana 4
GE - Georgia 4
KG - Kirghizistan 4
PS - Palestinian Territory 4
SK - Slovacchia (Repubblica Slovacca) 4
BW - Botswana 3
HR - Croazia 3
LV - Lettonia 3
NO - Norvegia 3
QA - Qatar 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
AL - Albania 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
CY - Cipro 2
ET - Etiopia 2
GA - Gabon 2
HN - Honduras 2
MD - Moldavia 2
NI - Nicaragua 2
Totale 516.111
Salva come PNG Salva come JPEG
Città #
Cagliari 455.503
Uta 26.252
Amsterdam 3.169
Fairfield 1.725
Ashburn 1.442
Woodbridge 1.326
Singapore 1.242
Dallas 1.044
Boardman 944
Houston 876
Chandler 843
Nyköping 709
Wilmington 708
Seattle 702
Ann Arbor 689
Cambridge 618
Jacksonville 591
Beijing 557
New York 383
Los Angeles 337
Hefei 267
Nanjing 215
Boston 214
Seoul 199
Helsinki 184
Santa Clara 183
Dong Ket 170
Ho Chi Minh City 150
Shanghai 149
Buffalo 140
Milan 138
Rome 136
Dearborn 125
San Diego 117
Hong Kong 106
São Paulo 105
Redondo Beach 84
Guangzhou 81
Chicago 76
Atlanta 72
Munich 70
Toronto 69
The Dalles 68
Hanoi 67
Redwood City 67
Shenyang 65
London 63
Nanchang 60
Hebei 59
Menlo Park 57
Mountain View 56
Nuremberg 55
Rio de Janeiro 55
Tianjin 54
Changsha 52
Warsaw 52
Phoenix 49
Norwalk 45
Council Bluffs 43
Tokyo 43
Vienna 41
Denver 38
Frankfurt am Main 38
Jiaxing 38
Brooklyn 37
Verona 35
Washington 35
Johannesburg 34
Orange 33
Chennai 32
Sassari 32
Jinan 31
Falls Church 29
Montreal 29
Pune 29
Brussels 27
San Jose 26
Zhengzhou 25
Lappeenranta 24
San Francisco 24
Baghdad 23
Düsseldorf 23
Orem 23
Paris 23
Stockholm 23
Auburn Hills 20
Hangzhou 20
Poplar 20
Bologna 19
Manchester 19
Mumbai 19
Sydney 19
Ankara 18
Belo Horizonte 18
Haiphong 18
Naples 18
Ningbo 18
Turku 18
Curitiba 17
Da Nang 17
Totale 504.750
Salva come PNG Salva come JPEG
Nome #
Patient-Physician Communication in Acute Myeloid Leukemia and Myelodysplastic Syndrome 240.421
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis 4.509
HLA-G expression and role in advanced-stage classical Hodgkin lymphoma 3.557
Leucocyte classification for leukaemia detection using image processing techniques 3.507
Comparison Between an Artificial Neural Network and Logistic Regression in Predicting Long Term Kidney Transplantation Outcome 3.402
Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 3.352
Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma 3.346
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients 3.320
What unrelated hematopoietic stem cell transplantation in thalassemia taught us about transplant immunogenetics 3.284
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients 3.277
HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia 3.189
Reassessing the approach to informed consent: The case of unrelated hematopoietic stem cell transplantation in adult thalassemia patients 3.024
Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study 2.889
KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation 2.867
Kir haplotype aa is a possible predictive marker of complete molecular response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia 2.767
Ruolo del trapianto allogenico nelle talassemie 2.721
The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma 2.711
Absence of histological myopathy in chronic myeloid leukemia patients complaining of muscle spasms and myalgia during treatment with nilotinib 2.685
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 2.566
Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients 2.544
A genome-wide association study by ImmunoChip reveals potential modifiers in myelodysplastic syndromes 2.490
Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia 2.238
Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors 2.190
Health related quality of life in patients with onco-hematological diseases 2.190
Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 2.161
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 2.092
Role of human leukocyte antigen-G 14-base pair polymorphism in kidney transplantation outcomes 2.078
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 2.076
Homozygosity for Killer Immunoglobin-like Receptor (KIR) Haplotype a Is Associated to Negative Interim Positron Emission Tomography (PET) and a Favourable Outcome in Hodgkin Lymphoma 2.020
Ethical issues of unrelated hematopoietic stem cell transplantation in adult thalassemia patients 1.948
Recipient CTLA-4*CT60-AA genotype is a prognostic factor for acute graft-versus-host disease in hematopoietic stem cell transplantation for thalassemia 1.933
Ruxolitinib therapy and telomere length in myelofibrosis 1.916
Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life 1.910
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice 1.855
Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis 1.812
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 1.804
THE HLA-G 14-BP POLYMORPHISM IS AN INDEPENDENT GENETIC RISK MARKER OF LONG-TERM KIDNEY TRANSPLANTATION OUTCOME 1.785
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 1.780
null 1.759
The human leukocyte antigen-g 14-bp polymorphism is an independent genetic risk marker of long-term kidney transplantation outcome 1.733
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review 1.695
Increased incidence of infection in patients with myelofibrosis and transfusion-associated iron overload in the clinical setting 1.636
Acute basophilic leukemia with U2AF1 mutation 1.557
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 1.554
Defibrotide in the COVID-19 coagulopathy: what is the timing? 1.550
Thresholds for clinical importance were defined for the EORTC CAT Core - an adaptive measure of core quality of life domains in oncology clinical practice and research 1.542
Systemic Mastocytosis with Associated Primary Myelofibrosis 1.532
Unrelated bone marrow transplantation in Thalassemia. The experience of the Italian Bone Marrow transplant Group (GITMO) 1.529
T cell tyrosine phosphorylation response to transient redox stress 1.522
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 1.514
Erythroblast morphology in refractory anemia with ring sideroblasts and thrombocytosis 1.509
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 1.507
Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research 1.491
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 1.467
Multifactorial pathogenesis of COVID-19-related coagulopathy. Can defibrotide have a role in the early phases of coagulation disorders? 1.452
Successful and safe stem cell mobilization using plerixafor in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia 1.435
Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report 1.431
Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation 1.425
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency 1.421
Return to normal life after hematopoietic stem cell transplantation for thalassemia: a study of patients transplanted from matched sibling donors 1.420
null 1.419
Perls stain grade in bone marrow aspirate correlates with overall survival in low-risk myelodysplastic patients 1.407
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients 1.369
Resolution of capillary leak syndrome by extracorporeal membrane oxygenation 1.363
The usefulness of artificial neural networks in predicting the outcome of hematopoietic stem cell transplantation 1.352
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy 1.321
A simulated case of chronic myeloid leukemia: the growing risk of Munchausen’s Syndrome by internet 1.296
Systemic mastocytosis with associated BCRABL1-negative atypical chronic myeloid leukemia 1.292
Interactions between killer immunoglobulin-like receptors and their human leucocyte antigen Class I ligands influence the outcome of unrelated haematopoietic stem cell transplantation for thalassaemia: a novel predictive algorithm 1.287
Immunological deregulation in classic hodgkin lymphoma 1.280
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 1.273
Rectal involvement in pre-early T acute lymphoblastic leukemia 1.273
Comparison between an artificial neural network and logistic regression in predicting acute graft-versus-host disease following unrelated donor hematopoietic stem cell transplantation in thalassemia patients 1.272
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major 1.256
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: A multicentre, prospective, observational, cohort study 1.202
Cytomegalovirus reactivation in patients under immunosuppressive treatment for autoimmune haemolytic anaemia 1.198
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes 1.177
The role of inhibitory KIR 2DL5 in the outcome of autologous hematopoietic stem cell transplantation for multiple myeloma 1.174
Kikuchi-Fujimoto disease associated with hemophagocytic lymphohistiocytosis following the BNT162b2 mRNA COVID-19 vaccination 1.163
White Blood Cell Count Nadir and Duration of Aplasia Do Not Associate with Treatment Outcome in Adult Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy 1.161
null 1.138
The usefulness of artificial neural networks in predicting the outcome of hematopoietic stem cell transplantation: a crystal ball to foresee the future? 1.128
null 1.128
null 1.110
Comparison between an artificial neural network and logistic regression in predicting acute graft-versus-host disease following unrelated haematopoietic stem cell transplantation 1.106
Evaluating the Thresholds for Clinical Importance of the EORTC QLQ-C15-PAL in Patients Receiving Palliative Treatment 1.100
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index 1.086
High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity 1.066
Complement-mediated oxidative damage of red cells impairs response to eculizumab in a G6PD-deficient patient with PNH 1.060
null 1.048
null 1.034
Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)? 1.031
Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned? 1.028
Paroxysmal nocturnal hemoglobinuria: clinical expression and response to treatment are modified by a unique interaction with co-existing glucose 6-phosphate dehydrogenase deficiency 1.017
Complement Activation in Paroxysmal Nocturnal Hemoglobinuria (PNH) Causes Oxidative Damage Which May Affect Response to Eculizumab 1.014
Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis 1.009
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study 986
null 984
Occurrence of immune thrombocytopenic purpura in a patient with essential thrombocythemia: How the immune system can overcome a neoplastic clone 984
Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment 980
Totale 416.469
Salva come PNG Salva come JPEG
Categoria #
all - tutte 622.650
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 622.650
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202126.231 0 0 0 0 0 6.431 5.338 3.686 1.243 4.278 3.109 2.146
2021/202217.322 1.674 1.367 820 915 1.235 1.281 835 875 1.405 2.021 2.587 2.307
2022/202322.185 1.654 2.475 2.451 1.687 2.012 2.372 961 2.724 1.364 1.400 2.052 1.033
2023/202426.605 1.275 1.050 1.468 1.954 2.229 4.706 3.680 1.828 1.345 2.031 2.505 2.534
2024/2025293.370 9.854 102.071 155.748 7.048 3.270 4.843 3.908 332 895 3.804 684 913
2025/20268.267 1.171 924 2.326 1.763 1.268 815 0 0 0 0 0 0
Totale 517.182